Martin Welschof
Andres McAllister
Ashley Robinson
Martin Welschof
PhD (Dr.rer.nat.) in recombinant antibody technology. Employed since 2018. He did his postdoctoral training at the German Cancer Research Center, Department for Recombinant Antibody Technology and at the University of Heidelberg, Department of Transplantation Immunology, Germany. Martin has a broad international experience from executive positions within the biotech industry, including Director of Technology at Axaron Bioscience AG, Heidelberg, Germany, CEO of Affitech (Nasdaq Copenhagen) and CEO of Opsona Therapeutics, Dublin, Ireland. Member of the Board of Anocca, APIM Therapeutics AS and Nextera AS. Born 1961.
Shareholding: 22,400
Conditional Employee Options: Option program 2023/2025: 48,000, Option program 2024/2026: 30,000, Option program 2025/2027: 14,000
Andres McAllister
Doctor in Medicine and Surgery from the Universidad del Rosario (Bogotá) and holds a PhD from the Institut Pasteur/Université Paris 7. Employed since 2017. He has performed academic work at the Pasteur Institute and the University of California, San Francisco on cancer immunotherapy. Andres was previously Chief Scientific Officer at Debiopharm, and has previously held senior roles at IDM and BioMérieux/ Pierre Fabre. Born 1956.
Shareholding: 3,009
Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000
Ashley Robinson
Has 25 years’ of experience in capital markets and corporate strategy experience. Employed since 2024. Before joining BioInvent, he served as Managing Director at LifeSci Advisors, where he established an office in Boston, advising key clients in the healthcare sector. Prior roles have been healthcare product specialist and sector head at Guggenheim Securities, Managing Director and Senior Partner at Leerink Partners, Vice President of ECM at Lehman Brothers. Born 1977.
Shareholding: -
Conditional employee options: Option program 2025/2027: 7,000
Björn Frendéus
Kristoffer Rudenholm Hansson
Stefan Ericsson
Björn Frendéus
Doctor of Immunology. Employed since 2001. Frequent publisher in leading scientific immunology journals, and speaker and chair at international Immuno-oncology conferences. Inventor on more than 150 patents and patent applications. Visiting Professor at University of Southampton. Born 1973.
Shareholding: 23,089 (own and affiliated holdings)
Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000
Kristoffer Rudenholm Hansson
Master of Science in Chemical engineering. Employed since 2016 and is responsible for process development and production of antibodies for clinical studies. He has 25 years of experience from managing manufacturing of antibodies and other proteins for clinical use. Kristoffer has held numerous positions within CMC Biologics A/S (now AGC Biologics), DAKO A/S and Symphogen A/S. Born 1974.
Shareholding: 22,303 (whereof 7,177 in endowment insurance)
Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000
Stefan Ericsson
MBA, Lund University. Employed since 1998. Chief Financial Officer since 2016 and has previously served as Director Business Control. Previous experience from the Swedish Tax Agency and as auditor at PricewaterhouseCoopers. Born 1963.
Shareholding: 8,000
Conditional Employee Options: Option program 2023/2025: 24,000, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000
Sylvie Ryckebusch
Ingunn Munch Lindvig
Sylvie Ryckebusch
PhD in neurobiology from the California Institute of Technology and BSc degrees in physics and mathematics from the University of Maryland, College Park. Consultant since 2020. 25 years of experience in business development, alliance management, and corporate strategy with extensive experience negotiating complex deals. Sylvie has served in senior positions at Serono, Merck KGaA, numerous biotechs, and Medicxi Ventures as well as McKinsey & Company and the Harvard Business School. Born 1965.
Shareholding: 22,870 (own and affiliated holdings)
Conditional Employee options: -
Ingunn Munch Lindvig
PhD in Biology from the University of Oslo. Employed since 2023. Experienced regulatory affairs leader who has worked across all stages of product development and has hands-on experience of the US and EU regulatory systems. Previously Vice President and Head of Regulatory Affairs at Circio, Head of Regulatory Affairs at Nordic Nanovector and also held senior regulatory positions at Photocure and Nycomed/ GE Healthcare. Born 1965.
Shareholding: -
Conditional employee options: Option program 2023/2025: 19,741, Option program 2024/2026: 15,000, Option program 2025/2027: 7,000
Leonard Kruimer
Natalie Berner
Elin Birgersson
Leonard Kruimer
Chairman of the Board since 2018.
MBA, CPA. He served as a Board Member in BioInvent between 2016– 2017. He has held senior executive and board positions at European and US based biotech companies. He held senior executive positions at royal Boskalis NV, GE Capital and Continental Canada Company and has been a consultant with McKinsey and an auditor with Price Waterhouse New York. Born 1958.
Other board appointments: Board member in Zealand Pharma A/S, Basilea International AG and Pharming Group NV. Director in AI Global Investments (Netherlands) PCC Ltd.
Shareholding: 33,538
Natalie Berner
Member of the Board since 2022.
BA in Community Health from Brown University and a Certificate in Premedical Sciences from Columbia University. Previous Research Associate at the New York University School of Medicine. Currently Managing Director, Therapeutics at Redmile Group, LLC. Born 1990.
Other board appointments: Hansa Biopharma AB, Redx Pharma Plc and Sensorion SA.
Shareholding: -
Elin Birgersson
Member of the Board since 2023.
MSc in Chemical biology. Elin has worked at the university (KTH) and pharma and biotech industry since 2012 and has experience in antibody discovery and high-throughput analysis. Born 1985.
Other board appointments: -
Shareholding: 92 (affiliated holdings)
Conditional Employee Options: Option program 2023/2025: 2,549; Option program 2024/2026: 1,781; Option program 2025/2027: 1,283
Kate Hermans
Nanna Lüneborg
Bernd Seizinger
Kate Hermans
Member of the Board since 2026.
Master’s degree in international management from the Thunderbird School of Global Management and a bachelor's degree Magna Cum Laude in International Relations from Wheaton College. Completed Part I of the CEDEP International General Management Program at INSEAD. More than 35 years of leadership experience across large public enterprises and venture-backed biotechs, with multiple successful exits. Kate has held senior roles including Interim CEO and President of Ambrx Biopharma, as well as senior leadership positions at 83bar LLC, Radius Health, Bristol Myers Squibb, Pfizer/Wyeth, and Intel, working in the U.S., China, Africa, and globally. Kate is an active speaker across multiple industry forums. Born 1968.
Other board appointments: Chair of the Board of Clue by Biowink. Board member in Mid-Atlantic Diamond Ventures.
Shareholding: -
Nanna Lüneborg
Member of the Board since 2022.
PhD in Neuroscience from University College London, MBA from the University of Cambridge and a BA in Physiology and Psychology from the University of Oxford. Currently General Partner at Forbion. Prior experience with Apposite Capital and Novo Holdings. Nanna has previously served on the Board of Directors of publicly traded and privately held companies, including Capstan (acquired by Abbvie), Inversago Pharma (acquired by Novo Nordisk), Lava Therapeutics (LVTX), Numab (asset spin-out Yellow Jersey acquired by J&J), ReViral (acquired by Pfizer), NBE Therapeutics (acquired by Boehringer Ingelheim), ObsEva (OBSV), IO Biotech (IOBT), Inventiva (IVA), Orphazyme (ORPHA), NodThera (private), MinervaX (private), and Stargazer (private). Born 1975.
Other board appointments: Board member in Maplight Therapeutics (MPLT), Sparrow Pharma, F2G and Noema Pharma, board observer in Numab Therapeutics.
Shareholding: -
Bernd Seizinger
Member of the Board since 2018.
Doctor of Medicine and Doctor of Neurobiology. Previous experience as CEO and President of GPC Biotech, Executive Vice President and Chief Scientific Officer at Genome Therapeutics Corporation and Vice President of Oncology Drug Discovery and, in parallel, Vice President of Corporate and Academic Alliances, both at Bristol-Myers Squibb. Senior faculty positions at Harvard Medical School, Massachusetts General Hospital, and Princeton University. Born 1956.
Other board appointments: Board member and chairman of multiple public and private biotech companies in the United States, Europe, and Canada, including Oxford BioTherapeutics, CryptoMedix Inc., Oncolytics Biotech Inc., Aprea AB, and Aptose Inc. Advisory board member/Senior Advisor to Biotech Venture Capital Funds such as Pureos BioVentures
Shareholding: 66,000
Tomas Wall
Scott Zinober
Tomas Wall
Member of the Board since 2025.
Tomas has worked in IT Management since 2007 at companies in manufacturing, medical distribution, and pharma. Born in 1981.
Other board appointments: -
Shareholding: 1,240
Conditional Employee Options: Option program 2023/2025: 4,399. Option program 2024/2026: 2,749; Option program 2025/2027: 1,283
Scott Zinober
Member of the Board since 2026.
MBA from the MIT Sloan School of Management and a BA in Economics & Psychology from Williams College. More than 25 years of global public and private equity experience. He spent more than two decades at Viking Global Investors, where he held roles including Healthcare Analyst, Portfolio Manager, Senior Portfolio Manager, and Team Leader. He also served on Viking's Investment Steering Committee, Management Committee and the Viking Foundation Board. Earlier in his career, he focused on biotechnology investments at Putnam Investments. Born 1977.
Other board appointments: -
Shareholding: 50,000